ArticleFrontiers in immunology2022

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.

Zhaoliang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.